Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Pfizer reports Q3 vaccine sales decline amid challenging US market conditions

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion

Amgen confident in US biosimilar market’s strength as sales surge 52%

FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’

The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries

Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals

Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform

RedHill secures final $10.5M court judgment for enforcement

RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment

Bayer's finerenone approved in India for heart failure

The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more

Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia

Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval